Page 1 to 10

This is a published notice on the Find a Tender service: <u>https://www.find-tender.service.gov.uk/Notice/033879-2025</u>

Tender NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

NHS England

UK4: Tender notice - Procurement Act 2023 - <u>view information about notice types</u> Notice identifier: 2025/S 000-033879 Procurement identifier (OCID): ocds-h6vhtk-055064 Published 19 June 2025, 10:47pm

Changes to notice

This notice has been edited. The <u>previous version</u> is still available.

Adding in Tender documents to this notice.

Scope

Description

Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as noninfectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye

Commercial tool

Establishes a framework

Total value (estimated)

- £1,520,432,295 excluding VAT
- £1,824,518,754 including VAT

Above the relevant threshold

Contract dates (estimated)

- 1 December 2025 to 31 May 2027
- Possible extension to 31 May 2029

• 3 years, 6 months

Description of possible extension:

Option or options to extend (at the discretion of the Authority) up to maximum of 24 months.

Main procurement category

Goods

CPV classifications

- 33600000 Pharmaceutical products
- 33690000 Various medicinal products

Contract locations

• UK - United Kingdom

Lot constraints

Maximum number of lots a supplier can bid for: 1

Maximum number of lots a supplier can be awarded: 1

Description of how multiple lots may be awarded:

There is no maximum number of Lots that can be awarded in Lot 1 - In Lot 2 there are 4 sublots - suppliers can be awarded only one sub-lot (subject to the number of bidders - see tender pack for further details)

Lot 1. CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:

Description

CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: 7NAT (National)

Lot value (estimated)

- £709,529,158 excluding VAT
- £851,434,989 including VAT

Framework lot values may be shared with other lots

Same for all lots

CPV classifications, contract locations and contract dates are shown in the Scope section, because they are the same for all lots.

Lot 2. CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments a

Description

CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg

Lot value (estimated)

- £810,903,137 excluding VAT
- £973,083,765 including VAT

Framework lot values may be shared with other lots

Same for all lots

CPV classifications, contract locations and contract dates are shown in the Scope section, because they are the same for all lots.

Framework

Maximum number of suppliers

Unlimited

Maximum percentage fee charged to suppliers

0%

Further information about fees

N/A

Framework operation description

Please refer to the ITO Documents for the Operation Description

Award method when using the framework

Without competition

Contracting authorities that may use the framework

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

Contracting authority location restrictions

- UKH East of England
- UKG West Midlands (England)
- UKE Yorkshire and the Humber
- UKI London
- UKC North East (England)
- UKD North West (England)

• UKF - East Midlands (England)

Participation

Particular suitability

Lot 1. CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:

Lot 2. CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments a

Small and medium-sized enterprises (SME)

Submission

Enquiry deadline

7 July 2025, 1:00pm

Tender submission deadline

14 July 2025, 1:00pm

Submission address and any special instructions

The procurement documents are available for unrestricted and full direct access, free of charge at <u>https://health-family.force.com/s/Welcome</u> Additional info obtained from the abovementioned address Tenders must be submitted to the abovementioned address.

Tenders may be submitted electronically

Yes

Languages that may be used for submission

English

Award decision date (estimated)

31 July 2025

Award criteria

Name	Туре	
Price	Price	
Quality	Quality	

Weighting description

Please see ITO Pack.

Other information

Applicable trade agreements

• Government Procurement Agreement (GPA)

Conflicts assessment prepared/revised

Yes

Procedure

Procedure type

Open procedure

Documents

Associated tender documents

CM-PHS-25-5728 - ITO Documents Folder.zip

ITO Documents

Contracting authority

NHS England

• Public Procurement Organisation Number: PDPT-3135-BWWY

Wellington House, 133-135 Waterloo Rd

London

SE18UG

United Kingdom

- Contact name: NHS England
- Email: <u>b.kullootee@nhs.net</u>
- Website: https://www.england.nhs.uk/

Region: UKI45 - Lambeth

Organisation type: Public authority - central government